Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (2004)~* History of migraine of at least 1 year~* Migraine onset before the age of 50 years~* History of 1 - 8 migraine attacks per month~* Male or female subjects aged 18 to 65 years~* Female patients of child-bearing potential must be using a highly effective form of contraception (eg combined oral contraceptive, IUD, abstinence, vasectomized partner)~* Able and willing to return to the clinic for treatment within 4 hours of the onset of a migraine headache~* Able and willing to give written informed consent~Exclusion Criteria:~* History of life threatening or intolerable adverse reaction to any triptan~* Use of prescription migraine prophylactic drugs~* Pregnant or breast-feeding women~* Women of child-bearing potential not using highly effective contraception~* History or evidence of coronary artery disease, ischemic or hemorrhagic stroke, epilepsy or any other condition placing the patient at increased risk of seizures~* History of hypertension (controlled or uncontrolled)~* Sitting BP \>160mmHg systolic or \>90mmHg diastolic on 2 repeated measurements at screening~* Current use of hemodynamically active cardiovascular drugs~* History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol~* Significant renal impairment~* Previous participation in this clinical trial~* Participation in any clinical trial of an experimental drug or device in the previous 30 days~* Any medical condition or laboratory test which in the judgment of the investigator makes the patient unsuitable for the study~* Relatives of, or staff directly reporting to, the investigator~* Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to any excipient of COL-144

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lasmiditan (Type: EXPERIMENTAL): Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received intravenous infusion of placebo solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).